FORTIS INC./ CA3495531079 /
| 2024-09-09 12:49:16 PM | Chg. +0.35 | Volume | Bid1:00:08 PM | Ask1:00:08 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 40.50EUR | +0.87% | 673 Turnover: 27,257.13 |
40.50Bid Size: 249 | 40.79Ask Size: 248 | 19.73 bill.EUR | - | - |
GlobeNewswire
08-06
FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
07-23
Advisory: Fortis Inc. to Hold Teleconference on July 31 to Discuss Second Quarter 2024 Results
GlobeNewswire
07-02
Fortis Inc. to Hold Teleconference on July 31 to Discuss Second Quarter 2024 Results
GlobeNewswire
06-18
FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program ...
GlobeNewswire
06-10
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annu...
GlobeNewswire
05-23
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) ...
GlobeNewswire
05-15
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results
GlobeNewswire
04-24
Advisory: Fortis Inc. to Hold Teleconference on May 1 to Discuss First Quarter 2024 Results and Hold...
GlobeNewswire
04-24
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combinat...
GlobeNewswire
04-23
Maryland CareerQuest Connects Area Students with Training and Education Opportunities for Hands-On C...
GlobeNewswire
04-03
Fortis Inc. to Hold Teleconference on May 1 to Discuss First Quarter 2024 Results and Hold Annual an...
GlobeNewswire
04-02
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metast...
GlobeNewswire
03-28
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial ...
GlobeNewswire
03-19
AstriVax Rounds Out Executive Team with Chief Business Officer (CBO) Dr. Gregory Fanning
